Multicomponent Vaccines against Group A Streptococcus Can Effectively Target Broad Disease Presentations

• Published in: Vaccines (Basel) Vol. 9; no. 9; p. 1025
• Main Authors: Shaw, Helen A., Ozanne, James, Burns, Keira, Mawas, Fatme
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 15-09-2021; MDPI
• Subjects: Antibodies; Antigens; Antisera; Cardiovascular diseases; Clinical trials; Cloning; Collagen (type I); Complications; Coronary artery disease; Disease; E coli; Fibronectin; Group A Streptococcus; Heart diseases; IgG; IL-8; Immune response; Immune system; Immunity; Immunization; Immunoglobulin G; Infections; Intravenous administration; Laboratories; Life sciences; M protein; Mac1 protein; Mucosa; Opsonophagocytosis; Pharyngitis; Proteins; Rheumatic heart disease; Septic shock; Streptococcus; Streptococcus infections; Streptococcus pyogenes; Toxic diseases; Toxic shock syndrome; vaccine; Vaccines; Virulence; Virulence factors; United Kingdom > UK; United States > US; Germany
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines9091025

Group A Streptococcus (GAS) is an important global human pathogen, with a wide range of disease presentations, from mild mucosal infections like pharyngitis to invasive diseases such as toxic shock syndrome. The effect on health and mortality from GAS infections is substantial worldwide, particularly from autoimmune sequelae-like rheumatic heart disease (RHD), and there is currently no licenced vaccine. We investigated protein antigens targeting a broad range of GAS disease presentations as vaccine components in individual and combination formulations. The potency and functional immunity generated were evaluated and compared between groups. Antibodies against all components were found in pooled human IgG (IVIG) and an immune response generated following the subcutaneous immunisation of mice. A combination immunisation showed a reduction in IgG response for SpyCEP but an increase for Cpa and Mac-1 (IdeS). An opsonophagocytosis assay (OPA) showed the killing of GAS with immune sera against M protein and combination groups, with a lower killing activity observed for immune sera against other individual antigens. Specific antigen assays showed functional immunity against SpyCEP and Mac-1 from both individual and combination immunisations, with the activity correlating with antibody titres. However, efficient blocking of the binding activity of Cpa to collagen I and fibronectin could not be demonstrated with immune sera or purified IgG. Our data indicate that combination immunisations, while effective at covering a broader range of virulence factors, can also affect the immune response generated. Further, our results showed that an OPA alone is inadequate for understanding protection from vaccination, particularly when considering protection from immune evasion factors and evaluation of the colonisation leading to pharyngitis.